WO2015005553A1 - 루테리알의 형태특성을 이용한 질병의 진단방법 - Google Patents
루테리알의 형태특성을 이용한 질병의 진단방법 Download PDFInfo
- Publication number
- WO2015005553A1 WO2015005553A1 PCT/KR2014/000393 KR2014000393W WO2015005553A1 WO 2015005553 A1 WO2015005553 A1 WO 2015005553A1 KR 2014000393 W KR2014000393 W KR 2014000393W WO 2015005553 A1 WO2015005553 A1 WO 2015005553A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- disease
- type
- ruterial
- luterial
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 82
- 201000010099 disease Diseases 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000003745 diagnosis Methods 0.000 title claims abstract description 41
- 230000000877 morphologic effect Effects 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 102
- 201000011510 cancer Diseases 0.000 claims abstract description 75
- 210000004369 blood Anatomy 0.000 claims abstract description 54
- 239000008280 blood Substances 0.000 claims abstract description 54
- 238000004393 prognosis Methods 0.000 claims abstract description 29
- 230000004927 fusion Effects 0.000 claims description 23
- 210000001124 body fluid Anatomy 0.000 claims description 19
- 210000003495 flagella Anatomy 0.000 claims description 19
- 239000010839 body fluid Substances 0.000 claims description 18
- 210000003743 erythrocyte Anatomy 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 11
- 206010017758 gastric cancer Diseases 0.000 claims description 11
- 201000011549 stomach cancer Diseases 0.000 claims description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 238000001493 electron microscopy Methods 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 8
- 201000005787 hematologic cancer Diseases 0.000 claims description 8
- 206010038038 rectal cancer Diseases 0.000 claims description 8
- 201000001275 rectum cancer Diseases 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- XXACTDWGHQXLGW-UHFFFAOYSA-M Janus Green B chloride Chemical compound [Cl-].C12=CC(N(CC)CC)=CC=C2N=C2C=CC(\N=N\C=3C=CC(=CC=3)N(C)C)=CC2=[N+]1C1=CC=CC=C1 XXACTDWGHQXLGW-UHFFFAOYSA-M 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 201000009036 biliary tract cancer Diseases 0.000 claims description 6
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 claims description 5
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 201000003076 Angiosarcoma Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- -1 Mito-tracker Chemical compound 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- 238000004043 dyeing Methods 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 230000033001 locomotion Effects 0.000 abstract description 5
- 206010027476 Metastases Diseases 0.000 description 15
- 230000009401 metastasis Effects 0.000 description 14
- 239000011435 rock Substances 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 206010064571 Gene mutation Diseases 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000011521 glass Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 230000009172 bursting Effects 0.000 description 5
- 210000001808 exosome Anatomy 0.000 description 5
- 230000000938 luteal effect Effects 0.000 description 5
- 230000011987 methylation Effects 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010004593 Bile duct cancer Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000026900 bile duct neoplasm Diseases 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000003022 colostrum Anatomy 0.000 description 3
- 235000021277 colostrum Nutrition 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 206010063916 Metastatic gastric cancer Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001953 common bile duct Anatomy 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000010995 liver angiosarcoma Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010035603 Pleural mesothelioma Diseases 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Definitions
- the present invention relates to a method for diagnosing a disease using the morphological characteristics of luterial present in the body fluid discharged from the patient.
- Micromaterials such as microvesicles in the blood, have been previously recognized as substances having no special function. However, it is known from various experimental data that microvesicles also have various biological activities. For example, platelet-derived microvesicles have been shown to function to stimulate specific cells through surface proteins on vesicles (CD154, RANTES and / or PF-4; Thromb. Haemost. (1999) 82: 794 , or J. Boil. Chem. (1999) 274: 7545), It has been reported that physiologically active lipids (eg, HTET, or arachidonic acid) in platelet microvesicles have specific effects on specific target cells. (See J. Biol. Chem.
- characteristics of a substance such as vesicles present in a biological sample may provide information on diagnosis, prognosis or therapeutic diagnosis of the disease, thereby detecting the disease and There is a need to identify biological indicators that can be used to treat them.
- Cancer is still the number 1 mortality disease in most industrialized countries. The cancer cure rate is still low and the death toll from cancer continues to increase, resulting in a significant increase in household burdens and national health care costs. Cancer is a disease in which cells proliferate indefinitely and interfere with normal cell functions. Representatives of lung cancer, gastric cancer (GC), breast cancer (BRC), and colorectal cancer (CRC) are typical. Can occur in any organization.
- GC gastric cancer
- BRC breast cancer
- CRC colorectal cancer
- the diagnosis using the image the cancer is determined based on the X-ray image, nuclear magnetic resonance (NMR) image obtained using a contrast agent attached to the disease target material, but such an image Diagnosis is likely to be misdiagnosed, depending on the clinician's or proficiency of the reading, and has a drawback that is highly dependent on the precision of the device obtaining the image. Furthermore, even the finest instruments are unable to detect tumors of several millimeters or less, which makes them difficult to detect in the early stages of development.
- NMR nuclear magnetic resonance
- a patient or a disease-bearing person is exposed to high-energy electromagnetic waves that may cause a mutation of a gene, which may cause another disease, and has a disadvantage in that the number of diagnosis through the image is limited. .
- the present inventors have found that the disease can be diagnosed and predicted by observing the morphological characteristics of the micromaterial, Luterial ((Luterial), present in the body fluid discharged from the patient.
- Luterial (Luterial)
- An object of the present invention is to provide a method for diagnosing a disease using morphological characteristics of luterial existing in body fluids that have already been discharged from a patient.
- the present invention (a) the microscope to determine one or more of the number, size (diameter or area), shape, film formation and nano-tracking speed of the ruterials present in the body fluid discharged from the patient Measuring using; And (b) one or more of the measured number, size (diameter or area), shape, film formation, and nano tracking rate of the ruterials; Normal luterial; Or it provides a method for providing information for predicting the diagnosis and prognosis of the disease, comprising the step of comparing with red blood cells.
- the present invention also comprises the steps of: (a) measuring the form of luterial existing in the body fluids already discharged from the patient by electron microscopy; (b) determining the shape of the measured ruterial in a form selected from the group consisting of a single type, a fused type, a multi-fused type, and a membrane-fused type; And (c) determining a disease state based on the determined form.
- the method provides information for predicting diagnosis and prognosis of a disease.
- the present invention also includes the steps of: (a) measuring at least one of the number, size (diameter or area), morphology, encapsulation, and nano-tracking speed of the ruterials present in the body fluid discharged from the patient using a microscope; And (b) one or more of the measured number, size (diameter or area), shape, film formation, and nano tracking rate of the ruterials; Normal luterial; Or it provides a method of diagnosing or predicting the disease, comprising the step of comparing with red blood cells.
- the present invention also comprises the steps of: (a) measuring the form of luterial existing in the body fluids already discharged from the patient by electron microscopy; (b) determining the shape of the measured ruterial in a form selected from the group consisting of a single type, a fused type, a multi-fused type, and a membrane-fused type; And (c) determining a disease state on the basis of the determined form.
- 1 schematically shows the life cycle of luterial.
- Figure 2a shows a photograph taken with confocal laser scanning microscopy of the blood-derived luterial of the terminal patients with non-small cell lung cancer
- Figure 2b is fluorescent staining of the blood-derived ruterion of the terminal patients with non-small cell lung cancer with rhodamine 123
- Figure 2c shows a photograph taken by electron microscopy of blood-derived ruterion of the terminal patients with non-small cell lung cancer.
- Figure 3 shows a photograph of the blood-derived ruterial arranged by the size of the diameter to 100 ⁇ 1000nm or more by taking an electron microscope.
- Figure 4a shows a picture taken with a dark field microscope of normal blood luteiral (stage 1)
- Figure 4b shows a picture taken with a dark field microscope of normal luteal (stage 2) of blood
- Figure 4c shows a picture taken with a dark field microscope of normal luteal blood (stage 3)
- Figure 4d shows a picture taken with a dark field microscope of luteal (step 4) of blood at a stage above methylation (methylation)
- 4E shows a photograph taken with dark field microscope of luterial of blood (step 5) at the stage of gene mutation
- FIG. 4F shows dark field microscope of ruterial of blood (step 6) at the stage of gene mutation.
- Figure 4g is a picture taken with
- Figure 4g shows a picture taken with a dark field microscope of the luterial (stage 7) of blood in the tumor-related gene mutation step
- Figure 4h shows a picture taken with a dark field microscope of the luterial of blood (stage 8) in the stage of complex variation
- Figure 4i shows a picture taken with a dark field microscope of the ruterial (step 9) of blood derived from terminal cancer patients .
- Figure 5 shows a photograph taken with a dark field microscope of the mass-type ruterial.
- Figure 6 shows a photograph of a rod-shaped luterial taken with a dark field microscope.
- Figure 7 shows a photograph taken with a dark field microscope of the lung cancer patient-derived luterial (a: early; b-e: stage 2-3).
- FIG. 8 shows a photograph taken by a dark field microscope of a luterial derived from a breast cancer patient (a / b: early stage, c / d: middle stage; e: lymph, peritoneal and pericardial metastasis).
- Figure 9 shows a photograph taken with a dark field microscope of the luterial derived from pancreatic cancer patients (a: early; b-d: mid-term).
- Figure 10 shows a picture taken with a confocal laser scanning microscope of the luteri from the patient of the common Bile Duct Cancer bone / lung metastasis.
- Figure 11 shows a photograph taken with a dark field microscope of the luterial derived from patients with Pleural Mesothelioma.
- Figure 12 shows a picture taken with a dark field microscope of the luterial derived from thyroid cancer (medium) patient.
- Figure 13 shows a photograph taken with a dark field microscope of uteri cancer derived from ovarian cancer patients (a / b: mid-term).
- Figure 14 shows a photograph taken with a dark field microscope of the luterial derived from biliary tract cancer patients.
- Figure 15 shows a photograph taken with a dark field microscope of the luterial derived from a prostate cancer patient.
- Figure 16 shows a photograph taken with a dark field microscope of the luterial derived from acute lymphocytic leukemia patients (a: medium; b: rod-mass complex advanced).
- Figure 17a ⁇ c is a dark-field microscope photograph of the liver cancer patient-derived luterial (a: early; b / c: medium),
- Figure 17d is a confocal laser scanning microscope of the lung cancer from lung cancer patients metastasized It shows the picture taken.
- Figure 18 shows a picture taken by a confocal laser scanning microscope of the ruterial derived from angiosarcoma of liver patients.
- Figure 19a ⁇ c shows a picture taken with a dark field microscope of the luterial derived from colorectal cancer gastric cancer patients.
- Figure 21 shows a photograph taken with a dark field microscope of the luterial derived from the early gastric cancer patients.
- Figure 22 shows a photograph taken with a dark field microscope of luterial derived from early patients with rectal cancer (a: mass-rod advanced; b: mass).
- FIG. 23 shows a photograph of luterial derived from acute myeloid leukemia patient with a dark field microscope (a: mass-load progressive; b / c: mid-term).
- FIG. 24 shows a photograph taken by a dark field microscope of luterial derived from acute myeloid leukemia patient (mass-load progression type).
- 25a shows luterial derived from liver cancer patients with gastric metastasis
- 25b shows luterial derived from peritoneal metastatic gastric cancer patients
- 25c shows luterial derived from peritoneal and liver metastatic gastric cancer patients.
- FIG. 26 shows luterial derived from bone and lung metastatic rectal cancer patients
- FIG. 27 shows luterial derived from bone metastatic prostate cancer patients
- FIG. 28 shows luterial derived from lymphatic metastatic non-small cell lung cancer (NSCLC) patients
- FIG. 29 shows a photograph taken by a dark field microscope of a luteal bone derived from a bone metastasized kidney cancer patient
- FIG. 30 shows a photograph taken by a dark field microscope of a luteal derived from an acute lymphocytic leukemia patient.
- FIG. 31 shows a photograph of measuring the moving speed (nano tracking speed) of the ruterial using a natto tracker.
- the term “luterial” used in the present invention is a living organism existing in all animals, and is similar to that of a virus to about 500 nm (normal treatment step 50 to 500 nm / abnormal fusion step 800 nm or more).
- the micromaterial having a size is named by the inventor.
- the ruterial includes both DNA and RNA and is distinguished from exosomes or microvesicles in that they have adhesion and mobility.
- the substance present in the plant is referred to as "Luterion” (Luterion), the origin of the ruterial found in the blood, etc. is estimated to be plant-derived ruterion (Fig. 1).
- Mitochondria are identified by Janus green B and fluorescent dyes Rhodamine 123, Mitotracker, Acridine Orange, and DAPI, and the ruterial also mitochondria The color is confirmed by the same dye, and similar to mitochondria, it is a double-layered membrane structure that has not completed the internal cristae structure and is observed in the same laser wavelength range as mitochondria. May also be referred to as “mitochondrial analogues” or “proto-mitochondria”.
- Luterial is present in blood, saliva, lymphatic vessels, semen and vaginal fluids, breast milk (especially colostrum), cord blood, brain cells, spinal cord and bone marrow in animals including humans.
- horned animals have luterials within their horns.
- the ruterials are also expected to be involved in the regulation of cell cycle and cell growth as well as signaling, cell differentiation and cell death, among which we have found that ruterials are closely related to the diagnosis of cancer. .
- RNAi RNA interference
- RNAi RNA interference
- the information system in the RNA instructs to produce a protein that causes abnormal disease out of the normal orbit, it artificially interferes with the action to suppress the occurrence of diseases such as cancer.
- energy metabolism when the size is more than 200 ⁇ 500nm, if these ruterials do not play a normal role, it causes a critical disorder in homeostasis and ATP production, causing diseases in both respiration and energy metabolism Can be.
- the mutant ruterial that does not perform a normal role is different in size and shape due to different ecology and characteristics from normal luterial.
- normal luterials do not proliferate after forming double-spores, but similar to stem cells in the case of mutant luterials found in the blood of cancer patients or patients with chronic diseases. Infinitely multiplying from 600-800nm or more, some have a size of 200 ⁇ m (200,000nm) or more.
- Luterial differs in number, size (diameter or area), shape, film formation, and nano-tracking speed according to an individual's disease, and thus diagnoses or prognoses a disease through one or more of the above characteristics. It can be predicted. This can be seen by the difference in the number, size (diameter or area), shape, film formation, nano-tracking speed, etc. of the lutereals derived from healthy people without disease and the diseased people. . This difference is due to the presence or absence of luterial mutations and is termed “mutant luterial” to distinguish luterials from diseased persons from normal luterials from healthy persons.
- the diagnosis and prognosis of the disease are possible by observing the number and morphological or biochemical characteristics of the ruterials present in the body fluid discharged from the patient.
- the number of luterials in patients is smaller than that of normal patients, and in severe patients, the number is reduced to 20 to 80%. Therefore, if the number of luterial is less than 20% of normal people, it can be determined as a tumor suspected state.
- a mutant luterial having a size (long diameter) of 20 micrometers when found, it can be determined as a tumor suspected state.
- the long diameter of the ruterial is less than 20um, when the coating is formed on the outside of the mutant ruterial can be determined as a suspected malignant tumor.
- the mutant luterial has a long diameter of 20 ⁇ m or more, it may be determined as a benign tumor suspect state when the film is not completed.
- the present invention provides a method for preparing a human body, the method comprising: (a) measuring by means of a microscope one or more of the number, size, shape, film formation, and nano-tracking speed of ruterials present in body fluids that have already been released; And (b) one or more of the measured number, size, shape, film formation, and nano-tracking rate of the ruterials; Normal luterial; Or to compare information with red blood cells and provide information for predicting the diagnosis and prognosis of the disease.
- Luterial observed in the present invention can be isolated from the body fluids previously released from the patient.
- Prevented body fluids in the present invention may be blood, saliva, lymphatic vessels, semen, vaginal fluid, breast milk (particularly colostrum), umbilical cord blood, brain cells, spinal cord or bone marrow, but is not limited thereto.
- luterial derived from blood can be used.
- the disease can be diagnosed and the prognosis can be predicted by observing the luterial present in the collected blood sample or the ruterial separated from the blood under a microscope.
- the first separation step of separating serum from the blood A second separation step of separating the precipitate that does not pass through the filter having pores having a diameter of 100 nm to 2 mm from the separated serum; And washing the separated precipitate to obtain ruterial.
- the first separation step may include collecting blood from the patient and centrifuging for 5-15 minutes at 1200 ⁇ 5000rpm centrifugation.
- the second separation step is a step of obtaining a supernatant by removing a general micro-vesicles, such as exosomes (exosomes) using a centrifugation in the serum; And passing the obtained supernatant through a filter having pores having a diameter of 100 nm to 2 mm to separate a precipitate that does not pass through it. ExoQuix may be used to remove exosomes, but is not limited thereto.
- the washing may include washing the serum from which the precipitate is separated (which may be an exosome) with physiological saline.
- the cleaning may then further comprise maintaining the icing (4 degrees or less).
- the long diameter of the luterial observed or photographed in step (b) is 8-30 times the diameter of red blood cells; Alternatively, if the observed or photographed luterial area is 8 to 30 times the area of red blood cells, the disease may be determined as a suspected cancer.
- the normal person's luterial When observing or measuring the size of the ruterial, the normal person's luterial has a size of 100-250 nm, 250-800 nm in case of fatigue syndrome, 800 nm or more in case of disease, and a maximum of several hundred ⁇ m (about 200 ⁇ m). .
- the number of luterials observed or photographed in step (b) is 20% or less of a normal person, and the size (diameter) is 0.8 to 1 ⁇ m, it may be determined as a suspected disease occurrence state, and when it is 20 ⁇ m, a cancer suspected state may be determined.
- a film is formed on the outside of the mutant luterial, it may be determined as a cancer marker regardless of its size. In particular, when a film is formed and flagella (tentacle) is observed, it may be determined as a malignant severity factor . Film formation can be observed with a dark field microscope or an electron microscope.
- step (a) the shape of the ruterial may be observed or photographed, and in step (b), the disease may be determined according to the shape of the ruterial observed or photographed.
- the form of the rutirial may be selected from the group including a normal type, flagella type, mass (Mass: M) type, rod (L: L) type, and a complex type having a flagella on the outside. have.
- the ratio of the long diameter to the short diameter of the ruterial may be 1: 1 to 3: 1.
- the mass is densely rounded, and most of the membranes are open, and a ratio of long diameter to short diameter may be 3: 1 to 5: 1.
- the rod type has a pointed and angular shape, and most of the membrane is closed, and a ratio of long diameter to short diameter may be 5: 1 to 12: 1.
- the rod type may be a rod type 1 consisting of a single chain of circular or oval shape or a rod type 2 formed by combining two or more single chains.
- the complex type may be a rod type and a mass type fusion type, a rod type and rod type fusion type, or a mass type and mass type fusion type.
- the shape of the ruterial measured by observation or imaging is rod-type, lung cancer, breast cancer, pancreatic cancer, bile duct cancer, medullary mesothelioma, thyroid cancer, ovarian cancer, biliary tract cancer, prostate cancer, or lymphoid blood cancer
- Determining the marker factor if the mass type, liver cancer, hemangiosarcoma, colon cancer, uterine cancer, gastrointestinal cancer (stomach cancer), kidney cancer, rectal cancer or myeloid hematologic cancer development markers, if complex, severe blood cancer or
- the metastatic cancer suspected state is determined by the core Gin, and when the flagella appears, it may be characterized by determining the terminal tumor suspected marker.
- the mutant luterial form can be used to track the site of development.
- the cancer can be determined by the lung, breast, pancreas, bile duct, thyroid, ovary, biliary tract, prostate, or lymphoid blood.
- the cancer can be determined by liver, colon, uterus, and digestive organs (stomach). ), Kidney, rectal or myeloid blood.
- the original occurrence of the arm is the same as that of the rod, and in the case of a complex battle from the mass to the rod-type, the original occurrence of the arm is the same as the mass.
- the present invention can also determine nanotracking speed, which means the mobility of luterial, and determine the suspected stage 1 to 4 cancer according to the speed.
- nanotracking speed means the mobility of luterial
- the nano tracking speed of the ruterial measured by observation or imaging is 8.0 ⁇ 11nm / sec suspected stage 1 cancer, 2.5 ⁇ 8.0nm / sec when suspected stage 2 cancer, 0.5 ⁇
- the suspected stage 3 cancer may be determined.
- the suspected stage 4 cancer may be determined.
- the present invention (a) measuring the form of luterial existing in the body fluids already discharged from the patient by electron microscopy; (b) determining the shape of the measured ruterial in a form selected from the group consisting of a single type, a fused type, a multi-fused type, and a membrane-fused type; And (c) determining a disease state on the basis of the determined form.
- the present invention provides a method for preparing a human body, the method comprising the steps of: (a) measuring the form of luterial existing in the body fluid discharged from a patient by electron microscopy; (b) determining the shape of the measured ruterial in a form selected from the group consisting of a single type, a fused type, a multi-fused type, and a membrane-fused type; And (c) determining a disease state based on the determined form.
- the blood-derived ruterial is at least one dye selected from the group consisting of Rhodamine 123, Mitotracker, Acridine Orange, DAPI, and Janus green B. Coloring is confirmed by dyeing, and double layer and criste structures are confirmed on an electron microscope.
- Step (c) is determined as normal when the shape of the ruterial measured by the observation or photographing is 80-100% consistent with the form of a single form, and a disease suspected state when 80-100% matches the form of a fusion type. Determining the tumor suspected state when 80-100% matched the multiple fusion type, and determining the severe tumor suspected state when 80-100% coincided with the ruptured fused form.
- Serum was isolated by centrifuging 250 ⁇ l of blood collected from a late stage of non-small cell lung cancer at 1600 rpm for 10 minutes. 63 ⁇ l of SBI ExoQuick was added to the serum and centrifuged at 3000 rpm for 15 minutes, and then maintained for an additional 15 minutes to separate the upper layer that did not react with ExoQuick. The separated supernatant (supernatant) was filtered through a 100 nm microfilter to separate out precipitate that did not pass. This was washed several times with physiological saline and then maintained by icing (less than 4 °C) to separate the fine material ruterial.
- Example 1 Luterial isolated in Example 1 was observed using a confocal laser scanning microscope (FIG. 2a), stained with rhodamine 123, and confirmed using a confocal laser scanning microscope (FIG. 2b). , Positive reaction stained by Janus Green B was confirmed by light microscopy.
- the isolated ruterial was observed by making an electron microscope sample (FIG. 2C). After fixing the blood cells with MICA, the membrane was peeled off with a probe (Probe) to confirm the DNA and RNA (atomic microscope). Fixed solution Cell-Tack BD (Bioscience) or Glutaraldehyde / poly-L-lysine may be used instead of MICA. After application of Rhodamine 123 fluorescein reagent in a dark field microscope, and washed after 5 minutes and observed with an orange filter (506nm ⁇ 520nm bandpass filter) it was confirmed that the green color observed.
- FIG. 2a to 2c are photographs taken of the ruterial separated in Example 1, and as shown in FIG. 2b, when the luterial is fluorescently stained with rhodamine 123, it is specifically stained and observed by a confocal laser scanning microscope. .
- the ruterial is specifically stained with Janus green B and can be observed with an optical microscope. Color development can also be confirmed by mitotracker, acridine orange, and DAPI, which are fluorescent staining reagents.
- Luterial shown in Figure 2a has a maximum diameter of 718nm, that is, 0.718 ⁇ m, it can be confirmed that the coating was formed on the outside as shown in Figure 2c. Indeed, the experimental group was diagnosed with late non-small cell lung cancer. Therefore, in the diagnosis and prognosis prediction method of the disease according to the present invention, the diameter of the observed or photographed ruterial is 0.5 ⁇ m or more, and when an external coating is formed, it may be determined as a cancer suspected state.
- Figure 2c is an electron micrograph of the ruterial, the ruterial used in the diagnosis and prognosis prediction method of the disease according to the present invention as a membrane structure having a double membrane formed on the outside to confirm the internal structure of the Christie Can be.
- Example 3 Diameter measurement of various subject-derived ruterials (electron microscopy)
- Luterial was isolated from the blood of 30 subjects from normal subjects to terminal cancer patients in the same manner as in Example 1, and then the diameter of the ruterial was measured using an electron microscope.
- the method for diagnosing and prognosticing the disease according to the present invention may observe or photograph the diameter of the ruterial under a microscope, and determine that the disease is suspected when the diameter of the observed or photographed ruterial is 800 nm, that is, 0.8 ⁇ m or more ( Electron microscopy or atomic force microscopy can be observed at 0.45 ⁇ m). The maximum observed size under the microscope was 200 ⁇ m, but the maximum can increase with the patient.
- the encapsulated luterial of 800 nm (0.8 ⁇ m) of FIG. 3 was found in cancer-derived blood. Therefore, the method for diagnosing and prognosticing the disease according to the present invention may observe or photograph the diameter of the luterial under a microscope, and if the diameter of the observed or photographed ruterial is 0.8 ⁇ m or more, and a film is formed, the disease may be determined to be a cancer suspect state. have.
- Luterial was isolated from blood collected from 15 patients with stage 1, stage 2, stage 3, and stage 4 cancer in the same manner as in Example 1.
- the isolated luterial was placed in a buffer solution, stained with rhodamine 123, and the diameter thereof was measured using a confocal laser scanning microscope. Observation rates of luterial variants of 2 ⁇ m or more, ie, mutant ruterials, are as follows.
- mutant ruterials with diameters of 2 ⁇ m or more increased.
- mutant luterials with diameters of 2 ⁇ m or more were found in about 94% of patients, and the maximum size was 200 ⁇ m or more.
- the observation ratio of the mutant ruterials having a diameter of 0.5 to 5 ⁇ m was high in stage 1 to 3 cancer patients.
- the rate of mutant ruterial was higher than 5 ⁇ m.
- the method for diagnosing and prognosticing the disease according to the present invention is to determine the suspected state of cancer when the diameter of the luterial is observed or photographed under a microscope and the diameter of the observed or photographed ruterial is 1.0 to 200 ⁇ m, but the thickness is 20 ⁇ m or more. Formation can be determined as a suspected cancer.
- Blood from normal, chromosomal methylation abnormalities, patients with genetic mutations, patients with tumor-related genetic mutations, patients with tumor-associated genetic mutations (late prostate cancer), are covered with slide glass, covered with a glass of glass and a drop of dark field oil It was added and observed at 1000 magnification using a Nikon Eclipse Ni (1000 ⁇ ) with a dark field microscope.
- stage 1 the proportion of luterial morphology observed in patients with stage 1, stage 2, stage 3, and stage 4 cancer among the experimental group patients was calculated.
- Figures 4b to 4i are shown in the form of the ruterial taken according to Example 6 divided into 2 to 9 steps in the order of severity of disease, step 1 is shown in Figure 4a.
- FIGS. 4B and 4C show normal blood-derived luterials (stages 2 and 3), FIG. 4D shows blood-derived luterials (stage 4) of patients with methylation abnormality stages, and FIGS. 4E and 4F show gene mutation generation stage patients.
- Derived luterial stages 5 and 6
- Figure 4g is a tumor-derived gene mutation stage patient-derived ruterials (stage 7)
- Figure 4h is a tumor-related gene mutation stage patient-derived ruterials (stage 8)
- Figure 4i is a tumor Luterial (stage 9) from a related gene complex mutation stage patient (late prostate cancer) was taken.
- the circular material is red blood cells or white blood cells.
- shiny silver micromaterials are ruterials. Normally derived ruterials are smaller than red blood cells, and no fused or modified colony was found.
- FIG. 4D is a blood-derived ruterial of a patient whose chromosome begins to show an abnormal methylation stage. The size is larger than that of the classification stage 3 of FIG. 4C, but no modified colony has been found.
- 4E and 4F are images of blood-derived luterial of the gene mutation generation patient, and in particular, in the case of classification step 6 of FIG. 4F, it can be seen that fusion between the ruterials has progressed compared to the classification step 4 of FIG. 4D.
- Gene mutation stage patients of Figures 4e and 4f has not yet been mutation in the tumor-related genes.
- Figure 4g is a picture taken of the luteri derived from the blood of a patient with a mutation in a part of the tumor-related gene (stage 7), overwhelmingly large mutant ruterial more than 20 times the size of red blood cells compared to Figures 4e and 4f (mass ) Clusters were observed (central silver matter).
- Figure 4h is a photograph of the luteri derived from the blood of patients with complex mutations in tumor-related genes (classification step 8), the size is much larger than the classification step 7, it was observed as a rod type.
- Figure 4i is a picture of the luterial (step 9) of the terminal cancer-derived blood, unlike step 8 was observed in the form of flagella.
- Patients with flagellar mutant ruterials were classified as terminal cancer patients and the survival of flagellar cancer patients was 1-4 months.
- the survival time was within 2 months.
- Example 6 As a result of microscopic observation according to Example 6, it was confirmed that the blood-derived ruterial morphology appeared in a normal form, flagella form, mass form, rod form, and complex form.
- the observed or photographed ruterials do not cause additional fusion or bursting, and have a long diameter to short diameter ratio of 1: 1 to 3: 1.
- 4a to 4c are normal ruterials.
- the method for diagnosing and prognosticing a disease according to the present invention may be determined to be normal when the observed or photographed form of the ruterial is 80 to 100% consistent with the normal form.
- the flagella is a form in which the observed or photographed luterial causes deformation or fusion, and thus the flagella is provided on the outside, and in FIG. 4I, the flagella luterial is observed.
- the flagellar observation rate increased rapidly, and in stage IV cancer, 99.1% in stage IV cancer showed a flagellar luterial in almost all stage IV cancer patients.
- the method for diagnosing and prognosticing a disease according to the present invention may be determined as a terminal tumor suspected state when the observed or photographed form of luterial is 80 to 100% consistent with the form of flagella.
- the survival period of the patient diagnosed with the terminal tumor may be 1 to 4 months. In particular, in the case of flagella, long-term survival is impossible.
- the mass type (M) is an observed or photographed ruterial that causes bursting or fusion, and thus its size and shape are deformed from the normal type, and in an irregular volume form in which the difference between the long diameter and the short diameter is not large, preferably
- the ratio of long diameter to short diameter may be 3: 1 to 5: 1.
- 4G and 5 illustrate photographs of a mass-type ruterial taken by a dark field microscope according to Example 6, and various types of mass types are observed. As a control, the disease can be determined by comparing the observed or photographed luterial forms.
- Rod type (L) is the observed or photographed ruterial causes a burst (bursting), deformation, or fusion to form a rod (Rod), the length difference between the short diameter and the long diameter is larger than the mass type.
- the ratio of the long diameter to the short diameter may be 5: 1 to 12: 1.
- the rod shape is observed in various forms as shown in FIG. Rod 1 type consisting of a single chain of circular or oval shape; And it may include a rod type 2 formed by combining two or more single chain.
- the rod type 1 is a single luterial in the form of a rod, which may be due to bursting and / or deformation.
- the rod type 2 is formed in a rod form by combining two or more ruterials, which may be due to one or more of bursting, deformation, and fusion.
- the flagella may be included in the rod form in a large category in shape, but differ in that the flagella is extended. Therefore, it is possible to determine whether it is a rod type first and then a flagellar type.
- the complex type may be a fusion type of rod type and mass type.
- a part of the ruterial formed integrally may be referred to as a rod type and a part which is a mass type.
- Luterial was obtained from the blood obtained from patients diagnosed with various cancers (Table 3) or by the same method as in Example 1, and observed.
- the blood sample or luterial was placed in a buffer solution, buried in a slide glass, covered with a cover glass, and then a drop of darkfield oil was added and observed using a darkfield microscope (Nikon Eclipse Ni (1000 ⁇ )) and a confocal scanning microscope.
- liver cancer hemangiosarcoma, colon cancer, uterine cancer, gastrointestinal cancer (gastric cancer), rectal cancer and acute myeloid leukemia, mass type (M) luterial was observed.
- the site of cancer is the same as that of L type, but it can be determined that metastasis proceeds, and also from mass type to mass-load type (ML)
- the site of cancer is the same as that of type M, but metastasis can be determined.
- the method for diagnosing and prognosticing the disease according to the present invention when the form of the observed or photographed ruterial is rod-shaped, lung cancer, breast cancer, pancreatic cancer, cholangiocarcinoma, mesothelioma, thyroid cancer, ovarian cancer, biliary tract cancer, prostate cancer , Or lymphoid hematologic cancer.
- the method for diagnosing and prognosticing the disease according to the present invention is characterized in that when the observed or photographed form of luterial is a mass, liver cancer, hemangiosarcoma, colon cancer, uterine cancer, gastrointestinal cancer (gastric cancer), rectal cancer, kidney cancer or myeloid It can be determined by the state of blood cancer.
- the method for diagnosing and prognosticing the disease according to the present invention may be determined as a suspected state of hematologic or metastatic cancer when the form of luterial is complex, and as a terminal cancer suspected state when the flagella is detected. have.
- Luterial was obtained from the blood of patients with stage 1, stage 2, stage 3, and stage 4 cancer (15 patients each) in the same manner as in Example 1.
- the ruterial was placed in a buffer solution, stained with Janus Green B, and observed under an optical microscope.
- the motility criterion was measured by nano-tracking of the ruterial with nano-tracking of US 3i using 200nm luterial. Specifically, after observing the ruterial with a bright field microscope and setting the tracking at the center of the ruterial and operating the nano-specific tracking, the speed per second was calculated by indicating the real-time movement trajectory along with the movement of the ruterial (FIG. 31).
- Nano-tracking rate of the ruterial derived from cancer patients according to the present embodiment indicates the motility of the ruterial.
- the method for diagnosing and prognosticing the disease according to the present invention is stage 1 cancer when the nano tracking speed of the observed or photographed luterial is 8.0 to 11 ⁇ m / sec, stage 2 cancer, and 0.5 to 2.5 ⁇ m / for 2.5 to 8.0 ⁇ m / sec.
- sec it can be determined as 3 rock, and in the case of 0 ⁇ 0.5 ⁇ m / sec, it is determined as 4 rock.
- the ruterial When observed by electron microscopy, the ruterial may be in the form of a single, fused, multiple fused, or ruptured fused type, and based on this, the disease may be diagnosed and predicted.
- the single type is a form in which a single luterial is observed
- the fusion type is a form in which two to four luterial communities are fused and observed
- the multiple fusion type is a form in which the fused luterial community is fused in multiple layers.
- the fused type membrane is a form in which the membrane of the fused ruterial is expelled and the inner material is expelled.
- Luterial was obtained from blood of various subjects (30 patients) from normal subjects to terminal cancer patients in the same manner as in Example 1.
- the obtained ruterial was fixed to a slide glass, and the shape was observed or photographed using an electron microscope.
- Tumors were found in a number of patients in which multiple fusion ruterials were found. Therefore, multiple fusion ruterials are considered to be tumor suspected.
- FIG. 32A to c show photographs taken with an electron microscope sequentially in the form of a film-fused fusion type.
- FIG. 32A the luteiral colony forming the membrane gradually proliferated (FIG. 32B), and finally the membrane burst to explode the deformed particles inside (FIG. 32C).
- FIG. 32A the luteiral colony forming the membrane gradually proliferated (FIG. 32B), and finally the membrane burst to explode the deformed particles inside (FIG. 32C).
- Severe cancers have been found in a number of patients in which these membrane-ruptured fused ruterials have been found. Therefore, the fused ruterial membrane is considered suspected of serious cancer.
- the method for diagnosing and prognosticing the disease according to the present invention is determined to be normal when 80-100% of the monomorphic form is matched with that of the ruterial which is present in the blood and whose double layer and criste structure are confirmed on the electron microscope. If 80 ⁇ 100% match with the fusion type, it is determined as the suspected disease state.If 80 ⁇ 100% match with the multiple fusion type, it is determined as the suspected tumor state. If 100% match, a serious tumor suspect can be determined.
- the method for diagnosing and prognosticing a disease utilizes ruterial as a marker for diagnosing and prognosticing a disease, and in particular, diagnoses of cancer patients, whether treatments are effective, before and after treatment, and organs of treated patients. It can be used effectively to judge survival.
- the ruterial which is a micromaterial present in the body fluid discharged from the patient, as a marker for diagnosis and prognosis of the disease, in particular, the diagnosis, operation and treatment effects of cancer patients, before and after treatment, And it can be effectively used to determine the long-term survival of the treated patient.
- the cancer cell tissue size is 5mm or less, regardless of the carcinoma, there is an advantage that it is possible to determine the current state, recurrence, and long-term viability of the cancer disease.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nanotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Ecology (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
Description
직경 2㎛ 이상의 변이 루테리알 관측 비율 | |
1기암 | 72.2% |
2기암 | 83.5% |
3기암 | 91.3% |
4기암 | 93.6% |
편모형 관찰 비율 | |
1기암 | 2.3% |
2기암 | 7.2% |
3기암 | 13.6% |
4기암 | 99.1% |
암 종류 | 진행상태 | 루테리알 형태 | 도면 |
폐암 | 초기 | L | 도7a |
중기 | L | 도 7b~e | |
유방암 | 초기 | L | 도8a~b |
중기 | L | 도8c | |
중기 | L-M | 도8d | |
림프, 복막(Peritoneal) 및 심막(Pericardial) 전이 | L | 도8e | |
췌장암 | 초기 | L | 도9a |
중기 | L-M | 도9b | |
중기 | L | 도9c~d | |
담관암(Common Bile Duct Cancer) | 뼈/폐 전이 | L | 도11 |
흉막중피종 (Pleural Mesothelima) | L | 도11 | |
갑상선암 | 초기 | L | 도6 |
중기 | L | 도12 | |
난소암 | L-M | 도13a~b | |
담도암 | L | 도14 | |
전립선암 | L | 도15 | |
급성림프구성 백혈병 | L | 도16a | |
L-M | 도16b | ||
간암 | 초기 | M | 도17a |
중기 | M | 도17b~c | |
폐전이 | M | 도17d | |
간 혈관육종(angiosarcoma of liver) | M | 도18 | |
대장암 | M | 도19a~c | |
자궁암 | M | 도20 | |
위암 | M-L | 도21 | |
직장암 | 중기 | M-L | 도22a |
중기 | M | 도22b | |
급성골수성 백혈병 | 중기 | M-L | 도23a |
M | 도23b~c | ||
신장암 | 중기 | M-L | 도24 |
위암 | 간전이 | 복합형 | 도25a |
위암 | 복막전이 | 복합형 | 도25b |
위암 | 복막 및 간 전이 | 복합형 | 도25c |
직장암 | 뼈/폐 전이 | 복합형 | 도26 |
전립선암 | 뼈전이 | 복합형 | 도27 |
비소성폐암(NSCLC) | 림프전이 | 복합형 | 도28 |
신장암 | 뼈전이 | 복합형 | 도29 |
급성림프구성 백혈병 | 복합형 | 도30 |
나노 트랙킹 속도 | |
정상인 | 12㎛/sec 이상 |
1기암 | 8.0~11㎛/sec |
2기암 | 5.0㎛/sec 내외 (2.5~8.0㎛/sec) |
3기암 | 0.5~2.5㎛/sec |
4기암 | 운동성 없음 (0~0.5㎛/sec) |
Claims (15)
- (a) 환자에서 기 배출된 체액에 존재하는 루테리알의 수, 크기(직경또는 면적), 형태, 피막형성여부 및 나노 트랙킹 속도 중 하나 이상을 현미경을 이용하여 측정하는 단계; 및(b) 상기 측정된 루테리알의 수, 크기(직경 또는 면적), 형태, 피막형성여부 및 나노 트랙킹 속도 중 하나 이상을 정상인의 루테리알; 정상 루테리알; 또는 적혈구와 비교하는 단계를 포함하는, 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제1항에 있어서, 상기 체액은 혈액인 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제1항에 있어서, 상기 (a) 단계는 루테리알을 로다민123(Rhodamine123), 미토트랙커(Mito- tracker), 아크리딘 오렌지(Acridine Orange), DAPI, 및 야누스 그린 B (Janus green B)로 구성되는 군에서 선택되는 1 이상의 염색약으로 염색하여 발색하고, 측정하는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제1항에 있어서, 상기 루테리알은 혈액에서 혈청을 분리하는 단계; 상기 분리된 혈청에서 100nm~2mm의 직경의 공극을 구비하는 필터를 통과하지 않는 침전물을 분리하는 단계; 및 상기 분리된 침전물을 세정하는 단계를 포함하는 방법에 의해 분리되는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 (b)단계는 측정된 루테리알의 직경이 적혈구의 직경의 8~30배; 또는 측정된 루테리알의 면적이 적혈구의 면적의 8~30배일 경우, 질병을 암 의심상태로 결정하는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 (b)단계는 측정된 루테리알의 수가 정상인의 20%이하이고, 장직경이 20μm이상인 경우 암 의심상태로 결정하는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 (b)단계는 루테리알의 외부에 피막이 형성된 경우, 암 의심상태로 결정하는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제1항에 있어서, 상기 (b)단계에서 루테리알의 형태는 정상형, 외부에 편모가 구비된 편모형, 매스(Mass)형, 로드(Rod)형, 및 복합형을 포함하는 군에서 선택되는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제8항에 있어서, 상기 정상형은 루테리알의 장직경:단직경의 비가 1:1~3:1이고, 상기 매스(Mass) 형은 장직경:단직경의 비가 3:1~5:1이며, 상기 로드(Rod) 형은 장직경:단직경의 비가 5:1~12:1이고, 상기 복합형은 로드형간, 매스형간 또는 로드형과 매스형의 융합형태인 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제8항 또는 제9항에 있어서, 상기 (b)단계는 측정된 루테리알의 형태가 (i) 로드형일 경우, 폐암, 유방암, 췌장암, 담관암, 융막중피종, 갑상선암, 난소암, 담도암, 전립선암, 또는 림프구성 혈액암 발생상태로 결정하며, (ii) 매스형일 경우, 간암, 간혈관육종, 대장암, 자궁암, 소화기암(위암), 신장암, 직장암 또는 골수성 혈액암 발생상태로 결정하고, (iii) 복합형일 경우, 중증 혈액암 또는 전이암 의심상태로 결정하며, (iv) 편모형이 나타날 경우, 말기 종양 의심상태로 결정하는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 (b)단계는 측정된 루테리알의 나노 트랙킹 속도가 8.0~11μm/sec인 경우 1기암 의심상태로, 2.5~8.0μm/sec인 경우 2기암 의심상태로, 0.5~2.5μm/sec인 경우 3기암 의심상태로, 0.5μm/sec 미만인 경우 4기암 의심상태로 결정하는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- (a) 환자에서 기 배출된 체액에 존재하는 루테리알의 형태를 전자현미경으로 측정하는 단계;(b) 상기 측정된 루테리알의 형태를 단일형, 융합형, 다중 융합형 및 막이 터진 융합형으로 구성된 군에 선택되는 형태로 결정하는 단계; 및(c) 상기 결정된 형태를 기준으로 질병상태를 결정하는 단계를 포함하는, 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제12항에 있어서, 상기 체액은 혈액인 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제12항에 있어서, 상기 루테리알은 로다민123(Rhodamine123), 미토트랙커(Mito- tracker), 아크리딘 오렌지(Acridine Orange), DAPI, 및 야누스 그린 B (Janus green B)로 구성되는 군에서 선택되는 1 이상의 염색약으로 염색하여 발색이 확인되며, 전자현미경 상에서 이중막 및 크리스테 구조가 확인되는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
- 제12항 내지 제14항 중 어느 한 항에 있어서, 상기 (c)단계는 상기 측정된 루테리알의 형태가 단일형의 형태와 80~100% 일치할 경우 정상으로 결정하고, 융합형의 형태와 80~100% 일치할 경우 질병 의심상태로 결정하고, 다중 융합형의 형태와 80~100% 일치할 경우 종양 의심상태로 결정하고, 막이 터진 융합형의 형태와 80~100% 일치할 경우 중증 종양 의심상태로 결정하는 것을 특징으로 하는 질병의 진단 및 예후를 예측하기 위한 정보를 제공하는 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016525261A JP2016526688A (ja) | 2013-07-12 | 2014-01-14 | ルテリアルの形態学的特性を用いた疾病の診断方法 |
CN201480050194.4A CN106068455B (zh) | 2013-07-12 | 2014-01-14 | 使用Luterial的形态特征用于诊断疾病的方法 |
EP14823421.4A EP3021119A4 (en) | 2013-07-12 | 2014-01-14 | Method for diagnosis of diseases using morphological characteristics of luterial |
US14/904,507 US10338061B2 (en) | 2013-07-12 | 2014-01-14 | Method for diagnosis of diseases using morphological characteristics of luterial |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0082060 | 2013-07-12 | ||
KR20130082060 | 2013-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015005553A1 true WO2015005553A1 (ko) | 2015-01-15 |
Family
ID=52280202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/000393 WO2015005553A1 (ko) | 2013-07-12 | 2014-01-14 | 루테리알의 형태특성을 이용한 질병의 진단방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10338061B2 (ko) |
EP (1) | EP3021119A4 (ko) |
JP (1) | JP2016526688A (ko) |
KR (7) | KR20150007922A (ko) |
CN (1) | CN106068455B (ko) |
WO (1) | WO2015005553A1 (ko) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3096141A4 (en) * | 2014-01-14 | 2017-09-06 | Won Cheol Choi | Method for screening cancer prevention agent or anticancer agent using morphological characteristics of luterial |
EP3095875A4 (en) * | 2014-01-14 | 2018-01-03 | Won Cheol Choi | Luterial and method for isolating and culturing same |
US10071170B2 (en) | 2013-06-24 | 2018-09-11 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
US10406188B1 (en) | 2015-01-05 | 2019-09-10 | Luterion Co., Ltd. | Method for inhibiting telomerase in cancer cell using luterion |
US10569194B2 (en) | 2015-01-06 | 2020-02-25 | Luterion Co., Ltd. | Luterion and separating and culturing methods for same |
US10590384B2 (en) | 2014-01-14 | 2020-03-17 | Luterion Co., Ltd. | Luterial and method for isolating and culturing the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000022432A1 (en) * | 1998-10-08 | 2000-04-20 | Silvia Maria Doglia | A method for the detection of mitochondrial alterations |
KR20030033134A (ko) * | 2001-10-17 | 2003-05-01 | 장준근 | 적혈구의 물리적 특성을 이용한 질환 진단 장치 및 그진단 방법 |
WO2006054296A2 (en) * | 2004-11-17 | 2006-05-26 | Spectrum Dynamics Llc | Methods of detecting prostate cancer |
WO2009100029A1 (en) * | 2008-02-01 | 2009-08-13 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
US20090311664A1 (en) * | 2005-12-22 | 2009-12-17 | Yuman Fong | Method for Detection of Cancer Cells Using Virus |
WO2012135844A2 (en) * | 2011-04-01 | 2012-10-04 | Cornell University | Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1473945A (en) | 1973-05-24 | 1977-05-18 | Gen Electric | Method for preparing slides for blood evaluation |
US4581223A (en) | 1980-03-12 | 1986-04-08 | Lawrence Kass | Individual leukocyte determination by means of differential metachromatic dye sorption |
JPS6064909A (ja) | 1983-09-20 | 1985-04-13 | Shiseido Co Ltd | 化粧料 |
JPH0412243A (ja) * | 1990-05-02 | 1992-01-16 | Asahi Chem Ind Co Ltd | 直孔性フィルター及びその製造方法 |
JP2002223768A (ja) | 2001-01-31 | 2002-08-13 | Japan Science & Technology Corp | ヒトミトコンドリア蛋白質とこの蛋白質をコードするポリヌクレオチド |
US20040009518A1 (en) | 2002-05-14 | 2004-01-15 | The Chinese University Of Hong Kong | Methods for evaluating a disease condition by nucleic acid detection and fractionation |
US9176121B2 (en) | 2004-02-13 | 2015-11-03 | Roche Diagnostics Hematology, Inc. | Identification of blood elements using inverted microscopy |
JP5704590B2 (ja) | 2010-02-05 | 2015-04-22 | 国立大学法人東京農工大学 | サイズ選択マイクロキャビティアレイを用いた循環腫瘍細胞の検出 |
JP5673025B2 (ja) | 2010-11-26 | 2015-02-18 | ユーハ味覚糖株式会社 | 新規レスベラトロール誘導体 |
CN106574927A (zh) * | 2014-01-14 | 2017-04-19 | 崔元哲 | 使用luterial的形态学特征筛选癌症预防剂或抗癌剂的方法 |
EP3095875A4 (en) * | 2014-01-14 | 2018-01-03 | Won Cheol Choi | Luterial and method for isolating and culturing same |
-
2014
- 2014-01-14 JP JP2016525261A patent/JP2016526688A/ja active Pending
- 2014-01-14 CN CN201480050194.4A patent/CN106068455B/zh active Active
- 2014-01-14 US US14/904,507 patent/US10338061B2/en active Active
- 2014-01-14 EP EP14823421.4A patent/EP3021119A4/en not_active Withdrawn
- 2014-01-14 KR KR20140004524A patent/KR20150007922A/ko active Application Filing
- 2014-01-14 WO PCT/KR2014/000393 patent/WO2015005553A1/ko active Application Filing
-
2016
- 2016-09-22 KR KR1020160121307A patent/KR20160115886A/ko active Application Filing
-
2020
- 2020-01-13 KR KR1020200004143A patent/KR20200007065A/ko active Application Filing
- 2020-12-02 KR KR1020200166416A patent/KR20200139117A/ko not_active Application Discontinuation
-
2022
- 2022-03-21 KR KR1020220034643A patent/KR20220050844A/ko not_active Application Discontinuation
-
2023
- 2023-01-06 KR KR1020230002154A patent/KR20230009999A/ko active Application Filing
- 2023-12-18 KR KR1020230184721A patent/KR20240001089A/ko not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000022432A1 (en) * | 1998-10-08 | 2000-04-20 | Silvia Maria Doglia | A method for the detection of mitochondrial alterations |
KR20030033134A (ko) * | 2001-10-17 | 2003-05-01 | 장준근 | 적혈구의 물리적 특성을 이용한 질환 진단 장치 및 그진단 방법 |
WO2006054296A2 (en) * | 2004-11-17 | 2006-05-26 | Spectrum Dynamics Llc | Methods of detecting prostate cancer |
US20090311664A1 (en) * | 2005-12-22 | 2009-12-17 | Yuman Fong | Method for Detection of Cancer Cells Using Virus |
WO2009100029A1 (en) * | 2008-02-01 | 2009-08-13 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
WO2012135844A2 (en) * | 2011-04-01 | 2012-10-04 | Cornell University | Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers |
Non-Patent Citations (5)
Title |
---|
CARDIOVASC. RES., vol. 49, no. 5, 2001, pages 88 |
J. BIOL. CHEM., vol. 274, 1999, pages 7545 |
J. BIOL. CHEM., vol. 276, 2001, pages 19672 |
See also references of EP3021119A4 |
THROMB. HAEMOST., vol. 82, 1999, pages 794 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071170B2 (en) | 2013-06-24 | 2018-09-11 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
EP3096141A4 (en) * | 2014-01-14 | 2017-09-06 | Won Cheol Choi | Method for screening cancer prevention agent or anticancer agent using morphological characteristics of luterial |
EP3095875A4 (en) * | 2014-01-14 | 2018-01-03 | Won Cheol Choi | Luterial and method for isolating and culturing same |
US10590384B2 (en) | 2014-01-14 | 2020-03-17 | Luterion Co., Ltd. | Luterial and method for isolating and culturing the same |
US10624926B2 (en) | 2014-01-14 | 2020-04-21 | Luterion Co., Ltd. | Luterial and method for isolating and culturing the same |
US10406188B1 (en) | 2015-01-05 | 2019-09-10 | Luterion Co., Ltd. | Method for inhibiting telomerase in cancer cell using luterion |
US10569194B2 (en) | 2015-01-06 | 2020-02-25 | Luterion Co., Ltd. | Luterion and separating and culturing methods for same |
Also Published As
Publication number | Publication date |
---|---|
KR20150007922A (ko) | 2015-01-21 |
CN106068455B (zh) | 2018-05-11 |
KR20160115886A (ko) | 2016-10-06 |
EP3021119A4 (en) | 2017-04-19 |
KR20200007065A (ko) | 2020-01-21 |
JP2016526688A (ja) | 2016-09-05 |
US20160169870A1 (en) | 2016-06-16 |
US10338061B2 (en) | 2019-07-02 |
CN106068455A (zh) | 2016-11-02 |
KR20200139117A (ko) | 2020-12-11 |
KR20220050844A (ko) | 2022-04-25 |
EP3021119A1 (en) | 2016-05-18 |
KR20240001089A (ko) | 2024-01-03 |
KR20230009999A (ko) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015005553A1 (ko) | 루테리알의 형태특성을 이용한 질병의 진단방법 | |
Feller et al. | Immunohistology and aetiology of histiocytic necrotizing lymphadenitis. Report of three instructive cases | |
WO2011027956A2 (ko) | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 | |
CA2395325C (en) | Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques | |
EP1360203A1 (en) | Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions | |
WO2015108246A1 (ko) | 루테리알 및 그 분리·배양 방법 | |
WO2012091465A2 (ko) | 혈청 아밀로이드 a에 대한 단일클론항체 및 이를 생산하는 하이브리도마 세포 | |
JP6203846B2 (ja) | 腸細胞バリア機能不全を検出するための方法および組成物 | |
WO2020235757A1 (ko) | 퇴행성 뇌질환 치료용 후보약물의 스크리닝 방법 | |
Mintz et al. | Membrane difference in peripheral blood lymphocytes from patients with chronic lymphocytic leukemia and Hodgkin's disease. | |
Young et al. | Three year trial of endoscopic cytology of the stomach and duodenum. | |
WO2019013392A1 (ko) | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
Pinder et al. | Identification of a surface antigen on Loa loa microfilariae the recognition of which correlates with the amicrofilaremic state in man. | |
WO2020141893A1 (ko) | 항체가 결합된 엑소좀 분리용 나노와이어 및 이를 이용한 엑소좀 분리 방법 | |
WO2019035623A2 (ko) | 렉틴이 결합된 나노입자를 이용한 암 진단 방법 | |
Seymour et al. | Identification of cells expressing T and p28, 33 (Ia-like) antigens in sections of human lymphoid tissue. | |
Bullen et al. | Lymphocyte subpopulations in adult coeliac disease. | |
Prat et al. | Immunocytologic analysis of nasal cells obtained by nasal lavage: a comparative study with a standard method of cell identification | |
WO2021125477A1 (ko) | 프리온 단백질 특이적인 항체를 포함하는 의약 조성물 | |
Smith et al. | Tγδ Cell Subsets in Cord and Adult Blood | |
Chen | The diagnosis of colorectal cancer with cytologic brushings under direct vision at fiberoptic colonoscopy: A report of 59 cases | |
WO2012093754A1 (ko) | 포유동물 체내에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 | |
Nasirudeen et al. | Programmed cell death in Blastocystis hominis occurs independently of caspase and mitochondrial pathways | |
AU2021103347A4 (en) | Method for recognizing peripheral blood circulating tumor cell of tumor patient based on isolation by size of epithelial tumor cells | |
WO2022035222A1 (ko) | 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14823421 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016525261 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14904507 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014823421 Country of ref document: EP |